Contemporary Issues in Lung CancerJones & Bartlett Publishers, 2009 M02 12 - 364 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective Second Edition is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. |
From inside the book
Results 1-5 of 88
Page ix
... disease. Only by becoming more knowledgeable about lung cancer can we ever make progress to lengthen survival time and quality of life. The intent of this book is unchanged from the original first edition. It is to provide seasoned ...
... disease. Only by becoming more knowledgeable about lung cancer can we ever make progress to lengthen survival time and quality of life. The intent of this book is unchanged from the original first edition. It is to provide seasoned ...
Page 3
... disease and exposes more about disease prevalence, risk factors, disease progression, treatment options, and quality of life for the affected individuals. It is our duty as health professionals to stimulate more interest in researchers ...
... disease and exposes more about disease prevalence, risk factors, disease progression, treatment options, and quality of life for the affected individuals. It is our duty as health professionals to stimulate more interest in researchers ...
Page 4
... disease/Breast-Snapshot. pdf. Accessed July 7, 2008. NCI funding for lung cancer. 300 250 200 150 100 1 0 NCI Lung Cancer Research Investment $4.6B $4.7B $4.8B $4.7B $237.5M $273.5M $276.5M $266.1M $242.9M $4.2B 2 3 4 5 Lung Cancer ...
... disease/Breast-Snapshot. pdf. Accessed July 7, 2008. NCI funding for lung cancer. 300 250 200 150 100 1 0 NCI Lung Cancer Research Investment $4.6B $4.7B $4.8B $4.7B $237.5M $273.5M $276.5M $266.1M $242.9M $4.2B 2 3 4 5 Lung Cancer ...
Page 5
... disease. The highest group was between 65 and 74 years of age (Table 1–2). Although the lung is the second most com- mon site diagnosed for cancer, lung cancer re- mains the leading cause of cancer death in both men and women in the ...
... disease. The highest group was between 65 and 74 years of age (Table 1–2). Although the lung is the second most com- mon site diagnosed for cancer, lung cancer re- mains the leading cause of cancer death in both men and women in the ...
Page 7
... disease, whereas squamoid tumors are associated with increased sur- vival in advanced disease. SCLC is in a separate category because of its rapid proliferation, high growth fraction, and the early development of widespread metastases ...
... disease, whereas squamoid tumors are associated with increased sur- vival in advanced disease. SCLC is in a separate category because of its rapid proliferation, high growth fraction, and the early development of widespread metastases ...
Contents
Oncology Treatment Modalities | 45 |
Special Issues Facing Individuals with Lung Cancer | 117 |
Psychosocial Issues of Individuals with Lung Cancer | 231 |
Assistance and Resources for Individuals Facing Lung Cancer | 255 |
Media and Future Research Directions | 301 |
Index | 353 |
Other editions - View all
Common terms and phrases
adjuvant agents aprepitant associated bevacizumab breathing breathlessness Bruera carboplatin carcinoma cell lung cancer chemotherapy chronic cisplatin Clinical Oncology clinical trials combination diagnosis disease docetaxel dose drug dyspnea EGFR erlotinib etoposide evaluation evidence-based factors fatigue gefitinib gemcitabine gene improve increased individuals indoor radon Internet intervention irinotecan Journal of Clinical lung cancer patients Medicine ment metastatic months NCCN nicotine non-small cell lung NSCLC Nursing Forum Oncology Nursing Oncology Nursing Forum paclitaxel palliative palliative care patient navigation patients and families patients with lung pemetrexed phase postoperative potential pulmonary quit smoking radiation therapy radiotherapy radon randomized receptors regimen reported resection respiratory response rate risk role SCLC score screening Sekido side effects small cell lung smoking cessation stage strategies support group surgical survival rate Symptom Management Table tients tion tobacco topotecan toxicity treat treatment tumor versus vinorelbine weight loss